RYZ101 Therapy Delayed Tumor Progression in Late-Stage Trial
The drug showed promise for patients with advanced gastrointestinal and pancreatic cancers following prior radiation treatment.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Do you trust that major pharmaceutical companies are effectively developing life-saving cancer treatments?
Bristol Myers Squibb reported that its RYZ101 therapy successfully delayed disease progression in patients with advanced gastrointestinal and pancreatic tumors. The late-stage trial focused on individuals who had previously undergone Lutetium-177-based therapy.
Why it matters
This development represents a potential new treatment pathway for patients with advanced neuroendocrine tumors that have stopped responding to current standard-of-care options. It validates Bristol Myers Squibb's strategic acquisition of the therapy technology.
In a late-stage clinical trial, RYZ101 significantly delayed disease progression compared to standard-of-care treatments in patients with gastroenteropancreatic neuroendocrine tumors. The study evaluated patients who had previously failed Lutetium-177-based therapy.
The players
Bristol Myers Squibb
A global biopharmaceutical company focused on developing therapies for oncology, hematology, and immunology.
RayzeBio
A developer of targeted radiopharmaceutical therapies acquired by Bristol Myers Squibb for $4.1 billion.
The details
The RYZ101 therapy functions by using the radioactive isotope actinium-225 to deliver targeted radiation directly to tumor cells or tumor-associated tissue. This approach allows for the specific destruction of cancerous cells while minimizing damage to healthy surrounding tissue. The safety profile observed in this latest trial remained consistent with data from previous studies of the therapy.
Timeline
Bristol Myers Squibb reported the late-stage trial results on October 12, 2026.
Health Landscape
The use of RYZ101 builds upon the existing landscape of radiopharmaceutical treatments for gastroenteropancreatic neuroendocrine tumors. This therapy aims to address the clinical gap for patients whose disease has progressed despite undergoing prior Lutetium-177-based radiation.
If you or a loved one are managing advanced gastrointestinal or pancreatic tumors, this trial data is worth discussing with your oncologist. Future study results may further clarify which specific patient populations are most likely to benefit from this radiation-based approach.
The takeaway
The study suggests that targeted radioactive isotopes could be a viable next-step treatment for patients with limited options after standard radiation. Patients should monitor future medical meetings for detailed trial outcomes and maintain ongoing communication with their medical team.
Further reading
For more on advancements in oncology, visit our Cancer section.
Live Poll
Do you trust that major pharmaceutical companies are effectively developing life-saving cancer treatments?
